Scopus BioPharma is a clinical-stage biopharmaceutical company developing therapeutics targeting diseases. Co. has launched its Duet BioTherapeutics, Inc., which integrates the management and clinical development of immunotherapy (the Duet Platform). Co. has several licenses, a research agreement and a clinical research support agreement relating to the Duet Platform with City of Hope. The Duet Platform is comprised of complementary bifunctional oligonucleotides that each consist of a toll-like receptor 9 agonist linked with a signal transducer and activator of transcription 3 inhibitor: RNA silencing, CpG-STAT3siRNA; antisense, CpG-STAT3ASO; and DNA-binding inhibitor, CpG-STAT3decoy.
|
Free SCPS Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |